About Us

Our History

year 2008

2008

  • Agios Pharmaceuticals is founded in Cambridge, Mass., to unlock a new field of discovery in cellular metabolism
year 2009

2009

  • Labs opened in January 2009
  • Agios groundbreaking research establishes for the first time that the mutated metabolic gene IDH1 has novel enzyme activity consistent with an oncogene and publishes the article in Nature
  • Continued to build the company’s research platform
year 2010

2010

  • Entered into a global, strategic collaboration with Celgene Corporation to discover and develop novel cellular metabolism-related therapies
  • Together with collaborators at Memorial Sloan Kettering, Agios publishes landmark paper in Cancer Cell, potentially implicating IDH mutation in a distinct mechanism of acute myeloid leukemia (AML) pathogenesis
year 2011

2011

  • Closed a $78 million oversubscribed Series C financing
  • Expanded research focus into rare genetic metabolic disorders
  • Celgene exercised the option to extend the cancer metabolism research collaboration for another year
year 2012

2012

  • Discovered the first potent inhibitors of mutant IDH that lower tumor 2-HG in vivo and published the findings in the American Chemical Society Medicinal Chemistry Letters
  • Published article in Nature reinforcing the pathogenic role of IDH mutations in AML
year 2013

2013

  • Initiated first clinical study of enasidenib in patients with IDH2 mutant hematologic malignancies
  • Completed initial public offering on NASDAQ
  • Named a Technology Pioneer by the World Economic Forum
  • Presented the first preclinical data from Agios’ rare genetic diseases research program
  • Science publishes back-to-back articles by Agios interrogating the roles of mutated IDH2 in leukemia and IDH1 in glioma via specific pharmacological inhibition
year 2014

2014

  • Presented first clinical data from the enasidenib Phase 1 study
  • Initiated the first clinical trial of Ivosidenib in patients with IDH1 mutant hematologic malignancies
  • Initiated a second clinical study of Ivosidenib in patients with IDH mutant solid tumors
  • Initiated first-in-human, healthy volunteer study of AG-348, Agios’ first PKR activator
  • Initiated registration-enabling expansion cohorts in the Phase 1 study of enasidenib in IDH2 mutant hematologic malignancies
  • Presented the first clinical data from the Phase 1 healthy volunteer study of AG-348
  • The FDA granted enasidenib both Fast Track and Orphan Drug Designation
  • Celgene exercises option to license enasidenib worldwide, with Agios to co-commercialize in the U.S.
year 2015

2015

  • The FDA granted Ivosidenib both Fast Track and Orphan Drug Designation
  • FDA granted Orphan Drug Designation for AG-348 for the treatment of PK deficiency
  • Initiated Phase 1 study of AG-881 in patients with advanced solid tumors with an IDH mutation
  • Presented the first clinical data from the Phase 1 study of Ivosidenib in patients with IDH1 mutant solid tumors
  • Initiated the Phase 3 IDHENTIFY study of enasidenib in patients with AML
  • Initiated a Phase 1b study of enasidenib or Ivosidenib in combination with chemotherapy in patients with newly diagnosed AML
  • Initiated a Phase 2 study of AG-348 in adult, transfusion-independent patients with PK deficiency (DRIVE-PK)
year 2016

2016

  • Initiated a Phase 1/2 study of enasidenib or Ivosidenib in combination with VIDAZA® in patients with newly diagnosed AML
  • Entered into a global research collaboration with Celgene focused on metabolic immuno-oncology
  • Presented first data from the Phase 2 DRIVE-PK study of AG-348 in patients with PK deficiency
  • Initiated a Phase 3 study of ivosidenib in cholangiocarcinoma
  • Filed a New Drug Application, along with Celgene, with the U.S. FDA for enasidenib